Tubulis

Open enrollment with an early-phase pipeline tilt

According to ClinicalTrials.gov-derived indexes, Tubulis sits in the upper half of US sponsors by registered trial count (#4,885 of 15,742 sponsors by registered trial count).

2 total trials 2 currently recruiting early-phase tilt upper half by trial count

Tubulis: 2 sponsored US clinical trials, 2 recruiting.

Tubulis sponsors 2 registered US clinical trials on ClinicalTrials.gov, 2 of them currently recruiting. 0 of these trials are in Phase 3-4 (later-stage) and 2 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is SCLC, with 1 trials.

Mid-pack sponsor footprint

Tubulis is in the upper half of sponsors by trial count (#4,885 of 15,742 sponsors by registered trial count). Use the pipeline list and therapeutic areas to see what drives that mid-pack volume.

Open and recent trials

2 total, page 1 of 1

RECRUITING Phase 1

First in Human Study of TUB-030 in Patients With Advanced Solid Tumors

NCT06657222
RECRUITING Phase 1

FiH Study to Investigate Safety, PK and Efficacy of the NaPi2b ADC TUB-040 in Patients With PROC or r/r Adenocarcinoma NSCLC

NCT06303505

Phase Distribution

PhaseTrial count
Phase 1 2

Therapeutic Areas

SCLC 1
TNBC - Triple-Negative Breast Cancer 1
HNSCC 1
CRC 1
NSCLC 1
Advanced Solid Tumors 1
Non-Small Cell Lung Cancer 1
Ovarian Cancer 1

What is open in the Tubulis pipeline

2 recruiting of 2 indexed (100% open).

Phase mix: 0 late (III/IV) vs 2 early (I/II) (early-phase heavy).

Top condition: SCLC (1 trial), 7 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

Tubulis: open-pipeline peers nationwide

Peers matched on 2 registered trials and 100% open enrollment, not the therapeutic-area sidebar.

Tubulis sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 1.522.533.544.5 0%50%100%150% Total trials Recruiting share Tubulis1200 Pharma1ST Biotherapeutics3 Waves Wellness3EO HealthAAVantgarde Bio SrlAcorn BiolabsAcrivon TherapeuticsADARx Pharmaceuticals
Tubulis sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Tubulis sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 2 trials (± recruiting share)

Sponsors near 100% open enrollment (± trial volume)

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this Tubulis page

2 registered trials is a research-attention snapshot, not an endorsement of Tubulis or any single study.

  • 2 of Tubulis's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • SCLC is the condition Tubulis studies most, compare against other sponsors active in the same condition before evaluating a specific study. See SCLC trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Tubulis pipeline card: 2 registered trials from official public datasets.Report a data error.